BASKA Laryngeal Mask Airway in Either Volume or Pressure Controlled Ventilation in Laparoscopic Cholecystectomy

Overview

this study will be undertaken to compare the efficacy of BASKA mask in volume controlled and pressure controlled ventilation in laparoscopic cholecystectomy.

Full Title of Study: “Comparison of Efficacy of BASKA Laryngeal Mask Airway in Either Volume or Pressure Controlled Ventilation in Laparoscopic Cholecystectomy Comparative Clinical Trial”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 8, 2022

Detailed Description

Laparoscopic cholecystectomy is one of the most commonly performed surgical procedures and the laryngeal mask airway (LMA) is the most common supraglottic airway device used by the anesthesiologists to manage airway during general anesthesia. Use of LMA has some advantages when compared to endotracheal intubation, such as quick and ease of placement, a lesser requirement for neuromuscular blockade and a lower incidence of postoperative morbidity. However, the use of the LMA in laparoscopy is controversial, based on a concern about increased risk of regurgitation and pulmonary aspiration. The ability of these devices to provide optimal ventilation during laparoscopic procedures has been also questioned. The most important parameter to secure an adequate ventilation and oxygenation for the LMA under pneumoperitoneum condition is its seal pressure of airway The BASKA mask is a novel supraglottic airway device. It has many of the features of other supraglottic airways, These include; A non-inflatable cuff, that it is continuous with the central channel of the device. As the pressure increases with positive pressure ventilation, the cuff itself is 'inflated', this may improve the seal, reduce leak, and make ventilation more efficient

Interventions

  • Procedure: volume controlled ventilation
    • the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway
  • Procedure: pressure controlled ventilation
    • the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway

Arms, Groups and Cohorts

  • volume controlled ventilation
    • after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
  • pressure controlled ventilation
    • after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode

Clinical Trial Outcome Measures

Primary Measures

  • oropharyngeal leak pressure
    • Time Frame: Intra-operative
    • the oropharyngeal leak airway pressure will be used as a primary outcome to compare the efficacy of BASKA mask in volume controlled and pressure controlled ventilation in laparoscopic cholecystectomy and measuring leak pressure.

Secondary Measures

  • End tidal carbon dioxide
    • Time Frame: Intraoperative
    • End tidal carbon dioxide measurement to determine efficacy of ventilation

Participating in This Clinical Trial

Inclusion Criteria

  • patients scheduled for elective cholecystectomy laparoscopic surgery. – Age: 18-60 years. – ASA physical status: I-II. Exclusion Criteria:

  • Patient refusal. – History of cardiac disease, psychological disorders, respiratory diseases including asthma, renal or hepatic failure. – Patients who have high risk of regurgitation or aspiration based on history of gastro esophageal reflux, hiatus hernia, diabetes and gross obesity. – Neck pathology. – Patients who predicted difficult airway (based on a history of difficult airway, mouth opening was less than 2.5 cm, inter-incisor distance < 20 mm, cervical spine pathology, modified Mallampati class III/IV, or thyromental distance < 65 mm). – Preoperative sore throat.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hala Saad Abdel-Ghaffar, Principal Investigator – Assiut University
  • Overall Official(s)
    • Hala S Abdel-Ghaffar, MD, Principal Investigator, Assiut university hospitals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.